^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Nilotinib…Contraindicated mutations...T315I, Y253H, E255K/V, or F359V/C/I or G250E